BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25338681)

  • 1. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.
    Dai X; Chen A; Bai Z
    Sci Rep; 2014 Oct; 4():6566. PubMed ID: 25338681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
    Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
    Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
    Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
    Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD; Collins LC; Hu R; Tamimi RM
    Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
    Salagame U; Banks E; O'Connell DL; Egger S; Canfell K
    PLoS One; 2018; 13(11):e0205034. PubMed ID: 30403669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
    Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
    Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines.
    Ku JL; Park SC; Kim KH; Jeon YK; Kim SH; Shin YK; Noh DY; Im SA; Bang YJ; Han W; Kim WH; Park JG
    Int J Oncol; 2013 Dec; 43(6):2073-81. PubMed ID: 24141649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
    Yu KD; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
    [No Abstract]   [Full Text] [Related]  

  • 15. MicroRNA regulation of progesterone receptor in breast cancer.
    Gilam A; Shai A; Ashkenazi I; Sarid LA; Drobot A; Bickel A; Shomron N
    Oncotarget; 2017 Apr; 8(16):25963-25976. PubMed ID: 28404930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prioritizing breast cancer subtype related miRNAs using miRNA-mRNA dysregulated relationships extracted from their dual expression profiling.
    Hua L; Zhou P; Li L; Liu H; Yang Z
    J Theor Biol; 2013 Aug; 331():1-11. PubMed ID: 23619378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
    Du X; Li XQ; Li L; Xu YY; Feng YM
    Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.
    Garuti A; Rocco I; Cirmena G; Chiaramondia M; Baccini P; Calabrese M; Palermo C; Friedman D; Zoppoli G; Ballestrero A
    Gynecol Oncol; 2014 Feb; 132(2):389-96. PubMed ID: 24269902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.